Concepta's myLotus pregnancies now in double figures
UK-based women’s health care company has announced today that its proprietary fertility self-test platform myLotus has now facilitated pregnancies in double figures.
The first myLotus births are expected later on this year.
The birth of myLotus-conceived babies could lend itself as proof of concept for the technology, as it hopes to establish itself as an effective precursor to time-consuming and expensive fertility treatments.
The technology has also differentiated itself from other at-home fertility tests, by detecting the actual concentration of hormones-- an analysis not available through traditional ovulation tests.
And the company has been consciously building to reach consumers directly. In March, Concepta announced that myLotus would be available in Boots locations around the UK. Such a market path to consumers also sets up the technology as an alternative to the NHS.
Here in the UK, under NICE guidelines, women may be administered IVF treatments under the NHS only after two years of trying to conceive naturally, and if they’re under the age of 40.
And, the overall market for such tech alternatives is growing. Today, more than a quarter of women have used pregnancy apps and other technology aids to help them conceive, and 10% of women have spent more than £200 to increase their chances of getting pregnant.
Today, the fertility industry is worth more than £320 million in the UK alone.
For more news and updates on Concepta:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.